Article Sidebar

Download
PDF

Main Article Content

Abstract

RÉSUMÉ
Introduction. L’efficacité du traitement antirétroviral dans la restauration immunitaire dépend fortement du stade de l’infection et du taux de lymphocyte TCD4 au moment de l’introduction du traitement. Nous avons évalué le taux de lymphocytes TCD4 à la découverte de la séropositivité au VIH pour caractériser le niveau d’infection de chaque patient. Matériel et méthodes. C’est une étude transversale et descriptive qui s’est déroulée dans le laboratoire de virologie de la faculté de médecine de Libreville. Nous avons analysé les données de la cohorte DERIRADO. Résultats. Nous avons inclus 133 patients. L’âge médian était de 45 ans (Q1-Q3 :37 ; 52). La médiane de LTCD4 était de 388 cellules/mm3 (Q1-Q3 : 250 ; 556). Le diagnostic était avancé chez 112 (84%) patients. Conclusion. La découverte de la séropositivité au Virus de l’Immunodéficience Humaine est faite à un stade d’immunodépression avancé chez la majorité des patients. Ce constat relève la nécessité de mettre en route les politiques de sensibilisation pour cibler les populations clés et amener le plus grand nombre au dépistage de l’infection par le Virus de l’Immunodéficience Humaine si l’on veut diminuer la courbe de transmission.


ABSTRACT
Introduction. The effectiveness of antiretroviral therapy in immune restoration largely depends on the stage of infection and the TCD4 lymphocyte count at the time of treatment initiation. We evaluated the rate of TCD4 lymphocytes at the discovery of HIV seropositivity to characterize the level of infection of each patient. Methods. This was a cross sectional descriptive and analytic study whose setting was the laboratory of virology of the faculty of medicine of Libreville. Our data source was DERIRADO cohort. Results. We included 133 patients. The median age was 45 (Q1-Q3:37;52). The median LTCD4 was 388 cells/mm3 (Q1-Q3: 250; 556). The diagnosis was advanced in 112 (84%) patients. Conclusion. The diagnosis of seropositivity to the Human Immunodeficiency Virus is made at a stage of immunosuppression in the majority of patients. This highlights the need to implement sensitization policies to target key populations and bring as many people as possible to screening in order to reduce the transmission curve.

Article Details

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

How to Cite
Urlucha Marina , M. O., Bissiengou MP, Yéboah OR, Zoa Assoumou S, Kombila Koumavor AC, & Mbiguino A. (2023). Le Taux de Lymphocytes T CD4 au Diagnostic de la Séropositivité au Virus de l’Immunodéficience Humaine à Libreville, 2022. HEALTH SCIENCES AND DISEASE, 24(2). https://doi.org/10.5281/hsd.v24i2.4180
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Tiwari R, Wang J, Han H, Kalu N, Sims LB, Katz DA, et al. Sexual behaviour change following HIV testing services: a systematic review and meta‐analysis. J Intern AIDS Soc [Internet]. nov 2020 [cité 30 nov 2022];23(11). Disponible sur: https://onlinelibrary.wiley.com/doi/10.1002/jia2.25635
  2. Yoo M, Wang JS, Park SJ, Cha J ok, Jung Y, Chung YS, et al. Characteristics of recent HIV infection among individuals newly diagnosed as HIV-positive in South Korea (2008–2015). Sci Rep. 22 juin 2022;12(1):10515.
  3. Okoye AA, Picker LJ. CD4 + T-cell depletion in HIV infection: mechanisms of immunological failure. Immunol Rev. juill 2013;254(1):54‑64.
  4. Okomo Assoumou MC, Mouladje M, ikomey moudinde G, Adiogo D, Esiene A, Ndumbe P, et al. Valeurs des lymphocytes TCD4 et CD8 chez les donneurs de sang à Yaounde, Cameroun. Health Sci Dis [Internet]. 11 sept 2013 [cité 30 oct 2022];12(4). Disponible sur: https://www.hsd-fmsb.org/index.php/hsd/article/view/121
  5. Ananworanich J, Sacdalan CP, Pinyakorn S, Chomont N, de Souza M, Luekasemsuk T, et al. Virological and immunological characteristics of HIV-infected individuals at the earliest stage of infection. J Virus Erad. 2016;2:43‑8.
  6. Cao W, Mehraj V, Trottier B, Baril JG, Leblanc R, Lebouche B, et al. Early Initiation Rather Than Prolonged Duration of Antiretroviral Therapy in HIV Infection Contributes to the Normalization of CD8 T-Cell Counts. Clin Infect Dis. 15 janv 2016;62(2):250‑7.
  7. Parekh BS, Ou CY, Fonjungo PN, Kalou MB, Rottinghaus E, Puren A, et al. Diagnosis of Human Immunodeficiency Virus Infection. Clin Microbiol Rev. 19 déc 2018;32(1):e00064-18.
  8. Onywera H, Maman D, Inzaule S, Auma E, Were K, Fredrick H, et al. Surveillance of HIV-1 pol transmitted drug resistance in acutely and recently infected antiretroviral drug-naïve persons in rural western Kenya. Menéndez-Arias L, éditeur. PLoS ONE. 8 févr 2017;12(2):e0171124.
  9. Lima VD, Wang L, Sereda P, McLinden T, Barrios R, Montaner JSG. Estimation of time of HIV seroconversion using a modified CD4 depletion model. Morgan E, éditeur. PLoS ONE. 12 févr 2021;16(2):e0246135.
  10. Lau CY, Adan M, Maldarelli F. Why the HIV Reservoir Never Runs Dry: Clonal Expansion and the Characteristics of HIV-Infected Cells Challenge Strategies to Cure and Control HIV Infection. Viruses. 14 déc 2021;13(12):2512.
  11. Bonnet F, Le Marec F, Leleux O, Gerard Y, Neau D, Lazaro E, et al. Evolution of comorbidities in people living with HIV between 2004 and 2014: cross-sectional analyses from ANRS CO3 Aquitaine cohort. BMC Infect Dis. déc 2020;20(1):850.
  12. Jaafari Z, McFarland W, Eybpoosh S, Tabatabaei SVA, Bafti MS, Ranjbar E, et al. Barriers and facilitators of access to HIV prevention, care, and treatment services among people living with HIV in Kerman, Iran: a qualitative study. BMC Health Serv Res. 29 août 2022;22(1):1097.
  13. Lahuerta M, Patnaik P, Ballo T, Telly N, Knox J, Traore B, et al. HIV Prevalence and Related Risk Factors in Men Who Have Sex with Men in Bamako, Mali: Findings from a Bio-behavioral Survey Using Respondent-Driven Sampling. AIDS Behav. juill 2018;22(7):2079‑88.
  14. Gebremeskel AT, Omonaiye O, Yaya S. Multilevel determinants of community health workers for an effective maternal and child health programme in sub-Saharan Africa: a systematic review. BMJ Glob Health. avr 2022;7(4):e008162.
  15. Giguère K, Eaton JW, Marsh K, Johnson LF, Johnson CC, Ehui E, et al. Trends in knowledge of HIV status and efficiency of HIV testing services in sub-Saharan Africa, 2000–20: a modelling study using survey and HIV testing programme data. The Lancet HIV. mai 2021;8(5):e284‑93.
  16. Bulstra CA, Hontelez JAC, Otto M, Stepanova A, Lamontagne E, Yakusik A, et al. Integrating HIV services and other health services: A systematic review and meta-analysis. Nosyk B, éditeur. PLoS Med. 9 nov 2021;18(11):e1003836.
  17. Moyo F, Haeri Mazanderani A, Kufa T, Sherman GG. The geographic distribution of priority population groups for the elimination of mother-to-child transmission of HIV in South Africa. Morgan E, éditeur. PLoS ONE. 8 avr 2020;15(4):e0231228.
  18. Zuma K, Simbayi L, Zungu N, Moyo S, Marinda E, Jooste S, et al. The HIV Epidemic in South Africa: Key Findings from 2017 National Population-Based Survey. IJERPH. 1 juill 2022;19(13):8125.